A20 Inhibitors

A20, also known as TNFAIP3 (Tumor Necrosis Factor Alpha-Induced Protein 3), is a cytoplasmic protein with a multifaceted role in the regulation of inflammation and cellular survival. It functions primarily as a ubiquitin-editing enzyme, a process that involves the sequential removal and addition of ubiquitin molecules to specific substrates. Through its actions, A20 plays a pivotal role in modulating the Nuclear Factor kappa B (NF-κB) signaling pathway, a central regulator of immune and inflammatory responses. By controlling NF-κB activity, A20 ensures that inflammatory processes are self-limiting and do not escalate uncontrollably. As a negative feedback regulator, A20 is induced by NF-κB activation and, in turn, acts to terminate NF-κB signaling, thus maintaining cellular homeostasis. Given its central role in inflammation regulation, targeting A20 offers a strategy to modulate the immune response. A20 inhibitors are a class of molecules designed to specifically inhibit the function of A20, thereby influencing the NF-κB signaling pathway. By inhibiting A20, these molecules can amplify or prolong the NF-κB-driven inflammatory response, which might be beneficial in certain situations where enhanced immune activation is desired. The design and development of A20 inhibitors involve a deep understanding of the protein's structure, its ubiquitin-editing enzymatic activity, and its interactions with other cellular proteins. Structure-function studies on A20, combined with advanced computational methods, have enabled the identification of binding pockets or domains that can be targeted by small molecules.